MedPath

Abdera Therapeutics, Inc.

Abdera Therapeutics, Inc. logo
🇨🇦Canada
Ownership
Holding
Employees
11
Market Cap
-
Website
http://abderatx.com

Clinical Trials

1

Active:0
Completed:0

Trial Phases

1 Phases

Phase 1:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Phase 1
1 (100.0%)

Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy

Phase 1
Recruiting
Conditions
Small-Cell Lung Cancer (SCLC)
Large Cell Neuroendocrine Carcinoma of the Lung
Interventions
First Posted Date
2024-12-16
Last Posted Date
2025-06-04
Lead Sponsor
Abdera Therapeutics Inc.
Target Recruit Count
65
Registration Number
NCT06736418
Locations
🇺🇸

MD Anderson, Houston, Texas, United States

🇺🇸

Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States

🇺🇸

United Theranostics, Glen Burnie, Maryland, United States

and more 1 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.